Filtered By:
Source: Clinical Breast Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 29 results found since Jan 2013.
HDAC11 is related to breast cancer prognosis and inhibits invasion and proliferation of breast cancer cells
CONCLUSION: In conclusion, this study found that HDAC11 expression is positively correlated with the overall survival rate of patients. HDAC11 can inhibit the invasion and proliferation of breast cancer cells to a certain extent and can be used as a good prognosis marker.PMID:37559686 | PMC:PMC10408431
Source: Clinical Breast Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Hao Zhao Xu-Ming Zhang Sheng Xiao Zhen-Ru Wu Yu-Jun Shi Ming-Jun Xie Source Type: research
Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation
CONCLUSION: This study characterizes the antagonistic relationship between miR-218 and EGFR. It also demonstrates downstream functional effects of miR-218 overexpression, leading to anti-tumorigenic cellular changes.PMID:37088795 | DOI:10.1007/s00432-023-04750-x
Source: Clinical Breast Cancer - April 23, 2023 Category: Cancer & Oncology Authors: Franz-Josef Wischmann Fabian M Troschel Maj Frankenberg Bj örn Kemper Archana Vijaya Kumar Mark Sicking Sherif Abdelaziz Ibrahim Ludwig Kiesel Martin G ötte Hans Theodor Eich Burkhard Greve Source Type: research
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis
CONCLUSIONS: Our results show that anchorage-independent survival and growth of cancer cells are supported by changes in genes and proteins that drive glucose metabolism towards an enhanced lactate production. Notably, this finding is valid for all lung and breast cancer cell lines we have analyzed in different nutrient environmental conditions. broader Validation of this mechanism in other cancer cells of different origin will be necessary to broaden the role of ALDOC and ENO2 to other tumor types. Future in vivo studies will be necessary to assess the role of ALDOC and ENO2 in cancer metastasis.PMID:36945054 | PMC:PMC100...
Source: Clinical Breast Cancer - March 22, 2023 Category: Cancer & Oncology Authors: Claudia De Vitis Anna Martina Battaglia Matteo Pallocca Gianluca Santamaria Maria Chiara Mimmi Alessandro Sacco Francesca De Nicola Marco Gaspari Valentina Salvati Francesca Ascenzi Sara Bruschini Antonella Esposito Giulia Ricci Eleonora Sperandio Alice M Source Type: research
The prognostic value of DAAM2 in lower grade glioma, liver cancer, and breast cancer
CONCLUSION: DAAM2 had a specific value in foretelling the prognosis of LGG, LIHC, and BRCA. High expression level of DAAM2 has longer survival rates in LGG and LIHC. The knockdown of DAAM2 retards the proliferation, invasion, and migration of BRCA cells. This study provides a novel sight of DAAM2 into the exploration of a potential biomarker in pan-cancer.PMID:36790676 | DOI:10.1007/s12094-023-03111-x
Source: Clinical Breast Cancer - February 15, 2023 Category: Cancer & Oncology Authors: Zeying Li Xiao Wei Yichao Zhu Source Type: research
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
CONCLUSIONS: Our results indicate that EDI3 may be a potential novel therapeutic target in patients with HER2-targeted therapy-resistant ER-HER2 + breast cancer that should be further explored.PMID:36670508 | DOI:10.1186/s13046-022-02578-w
Source: Clinical Breast Cancer - January 20, 2023 Category: Cancer & Oncology Authors: Magdalena Keller Katharina Rohlf Annika Glotzbach Gregor Leonhardt Simon L üke Katharina Derksen Özlem Demirci Defne G öçener Mohammad AlWahsh J örg Lambert Cecilia Lindskog Marcus Schmidt Walburgis Brenner Matthias Baumann Eldar Zent Mia-Lisa Zischi Source Type: research
siRNA and targeted delivery systems in breast cancer therapy
Clin Transl Oncol. 2022 Dec 23. doi: 10.1007/s12094-022-03043-y. Online ahead of print.ABSTRACTRecently, nucleic acid drugs have been considered as promising candidates in treatment of various diseases, especially cancer. Because of developing resistance to conventional chemotherapy, use of genetic tools in cancer therapy appears inevitable. siRNA is a RNAi tool with capacity of suppressing target gene. Owing to overexpression of oncogenic factors in cancer, siRNA can be used for suppressing those pathways. This review emphasizes the function of siRNA in treatment of breast tumor. The anti-apoptotic-related genes including...
Source: Clinical Breast Cancer - December 23, 2022 Category: Cancer & Oncology Authors: Sepideh Mirzaei Mahshid Deldar Abad Paskeh Maliheh Entezari Seyed Hesamoddin Bidooki Vahideh Javadian Ghaleh Shamin Rezaei Elahe Sadat Hejazi Amirabbas Kakavand Mitra Behroozaghdam Abolfazl Movafagh Afshin Taheriazam Mehrdad Hashemi Saeed Samarghandian Source Type: research
The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer
CONCLUSIONS: Our findings describe a novel genomic feature in metastatic prostate cancer and suggest that PIK3R1 alteration may be a key event for insulin-PI3K-glycolytic pathway regulation in prostate cancer.PMID:35670774 | DOI:10.1158/1078-0432.CCR-21-4272
Source: Clinical Breast Cancer - June 7, 2022 Category: Cancer & Oncology Authors: Goutam Chakraborty Subhiksha Nandakumar Rahim Hirani Bastien Nguyen Konrad H Stopsack Christoph Kreitzer Sai Harisha Rajanala Romina Ghale Ying Z Mazzu Naga Vara Kishore Pillarsetty Gwo-Shu Mary Lee Howard I Scher Michael J Morris Tiffany Traina Pedram Ra Source Type: research
Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ER α expression and proliferation in luminal primary and metastatic breast cancer cells
CONCLUSIONS: CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs.PMID:35418303 | DOI:10.1186/s13046-022-02360-y
Source: Clinical Breast Cancer - April 14, 2022 Category: Cancer & Oncology Authors: Sara Pescatori Stefano Leone Manuela Cipolletti Stefania Bartoloni Alessandra di Masi Filippo Acconcia Source Type: research
YY1-Induced Transcriptional Activation of FAM111B Contributes to the Malignancy of Breast Cancer
CONCLUSION: YY1-induced transcriptional activation of FAM111B accelerated the progression of breast cancer.PMID:34802969 | DOI:10.1016/j.clbc.2021.10.008
Source: Clinical Breast Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Wei Li Sihui Hu Zhiqiang Han Xuejun Jiang Source Type: research
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer
CONCLUSIONS: These data suggest nuclear FGFR1 contributes to endocrine resistance by modulating gene transcription in ER+ breast cancer. Nuclear FGFR1 activity was unaffected by FGFR TKIs, thus supporting the development of treatment strategies to inhibit nuclear FGFR1 in ER+/FGFR1 overexpressing breast cancer.PMID:34011560 | DOI:10.1158/1078-0432.CCR-20-3905
Source: Clinical Breast Cancer - May 20, 2021 Category: Cancer & Oncology Authors: Alberto Servetto Rahul Kollipara Luigi Formisano Chang-Ching Lin Kyung-Min Lee Dhivya R Sudhan Paula I Gonzalez-Ericsson Sumanta Chatterjee Angel Guerrero-Zotano Saurabh Mendiratta Hiroaki Akamatsu Nicholas James Roberto Bianco Ariella B Hanker Ralf Kittl Source Type: research
The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
CONCLUSION: We confirm previous studies showing that the PTPN2 protein is lost in half of the breast cancer cases and gene deletion occurs in 15-18% of the cases. Furthermore, the results suggest that the role of PTPN2 is subtype-related and should be further investigated to assess how this could affect breast cancer prognosis and treatment response.
PMID: 31025094 [PubMed - indexed for MEDLINE]
Source: Clinical Breast Cancer - June 30, 2019 Category: Cancer & Oncology Authors: Veenstra C, Karlsson E, Mirwani SM, Nordenskjöld B, Fornander T, Pérez-Tenorio G, Stål O Tags: J Cancer Res Clin Oncol Source Type: research
Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis.
CONCLUSION: The data suggested that GNAS promoted breast cancer cell proliferation and migration (EMT) through the PI3K/AKT/Snail1/E-cadherin signaling pathway. These findings also indicate that GNAS can serve as a potential prognostic indicator and novel therapeutic target in breast cancer.
PMID: 30767161 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - February 14, 2019 Category: Cancer & Oncology Authors: Jin X, Zhu L, Cui Z, Tang J, Xie M, Ren G Tags: Clin Transl Oncol Source Type: research
Nuclear accumulation of UBC9 contributes to SUMOylation of lamin A/C and nucleophagy in response to DNA damage.
CONCLUSIONS: Our findings suggest that nuclear DNA leakage activates nucleophagy through UBC9-mediated SUMOylation of lamin A/C, leading to degradation of nuclear components including lamin A/C and leaked nuclear DNA.
PMID: 30744690 [PubMed - in process]
Source: Clinical Breast Cancer - February 11, 2019 Category: Cancer & Oncology Authors: Li Y, Jiang X, Zhang Y, Gao Z, Liu Y, Hu J, Hu X, Li L, Shi J, Gao N Tags: J Exp Clin Cancer Res Source Type: research
